




(FIG. 1.A)




FIG. 1.B




FIG. 2




FIG. 3




FIG. 4

Pilot PK Study

Simulation and Comparison of Plasma Profiles of Reference Versus Three Eurand Test Formulations




FIG. 5

Pilot PK Study

Plasma Profiles of Reference Versus Three Eurand Test Formulations




FIG. 6




FIG. 7




FIG. 8




FIG. 9





FIG. 10



T1: PF391EA001 (8 mg RR + 12 mg TPR with T_{80} of 8 hrs
T2: PF392EA001 (8 mg RR + 16 mg TPR with T_{80} of 8 hrs
T3: PF379EA001 (8 mg RR + 16 mg TPR with T_{80} of 12 hrs
Reference: Zofran 8 mg (BID 8 hrs apart)

FIG. 11